NeuroPace, Inc.

NasdaqGM NPCE

NeuroPace, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2024: 73.83%

NeuroPace, Inc. Gross Profit Margin is 73.83% for the Trailing 12 Months (TTM) ending September 30, 2024, a 2.45% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

NeuroPace, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was 72.06%, a -0.80% change year over year.
NeuroPace, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was 72.64%, a -2.78% change year over year.
NeuroPace, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was 74.72%.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

NasdaqGM: NPCE

NeuroPace, Inc.

CEO	Mr. Joel D. Becker
IPO Date	April 22, 2021
Location	United States
Headquarters	455 North Bernardo Avenue
Employees	184
Sector	Health Care
Industries Pharmaceuticals Telehealth Virtual Reality (VR)

Description

NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.

Key trends

Past 5 years